Regeneron Pharmaceuticals Inc. ($REGN) Stock Forecast: Down 0.4% Today

What is Regeneron Pharmaceuticals Inc.?

Regeneron Pharmaceuticals (REGN) is a leading biotechnology company known for its innovative treatments in various therapeutic areas, including ophthalmology and rare diseases. The stock experienced a significant bearish movement in today's market.

Why is Regeneron Pharmaceuticals Inc. going down?

REGN stock is down 0.4% on Feb 5, 2026 15:43

• The bearish movement in Regeneron's stock could be attributed to the overall negative sentiment surrounding the biotech sector, as highlighted by concerns over gene therapy safety issues at Sarepta Therapeutics and the competitive landscape.
• The selling of Ocular Therapeutix stock by its COO amidst a significant price drop and concerns about overvaluation in the sector may have added to the bearish pressure on biotech stocks, including Regeneron.
• Comments on Moderna and preference for other pharma and biotech names, particularly mentioning Regeneron as a more favorable option, could have influenced investor sentiment and contributed to the downward movement in Regeneron's stock price.
• The overall market perception of biotech companies may have led to profit-taking and a shift in investment focus away from companies like Regeneron, impacting its stock performance negatively.

REGN Price Chart

REGN Technical Analysis

REGN News

Sarepta Saga Has ‘Gone on Too Long’ as Competitors Catch Up

Sarepta Therapeutics is facing increasing skepticism from investors and patients following a series of deaths linked to its gene therapies, particularly Elevidys, for Duchenne muscular dystrophy (DMD). Despite defending its data, the company's stock has plummeted, and its Q4 2025 sales for Elevidys missed consensus estimates. With competitors like REGENXBIO nearing market entry and a tarnished brand, analysts question Sarepta's future viability and its ability to maintain its market position.

https://www.biospace.com/drug-development/sarepta-saga-has-gone-on-too-long-as-competitors-catch-up

Notman, Ocular Therapeutix COO, sells $101,396 in stock By Investing.com

Donald Notman, COO of Ocular Therapeutix (NASDAQ:OCUL), sold 11,490 shares totaling $101,396 in pre-arranged transactions to cover tax withholding obligations from restricted stock units. These sales occurred as the stock price dropped significantly, and InvestingPro data suggests the company is currently overvalued. Ocular Therapeutix has also seen recent key developments including new executive appointments, potential acquisition interest from Sanofi, and reiterated "Buy" ratings from analysts for its investigational retina treatment.

https://in.investing.com/news/insider-trading-news/notman-ocular-therapeutix-coo-sells-101396-in-stock-93CH-5222591

The Truth About Vertex Pharma: Why Wall Street Suddenly Can’t Shut Up

The article discusses why Vertex Pharmaceuticals (VRTX) is gaining significant attention from Wall Street and retail investors. It highlights Vertex's strong pipeline, particularly in gene editing and rare diseases, its robust financial performance, and compares it to a competitor, Regeneron Pharmaceuticals. The author concludes that Vertex is a strong "cop" for long-term growth investors willing to tolerate volatility and pay a premium for future potential, despite its high price.

https://www.ad-hoc-news.de/news/ueberblick/the-truth-about-vertex-pharma-why-wall-street-suddenly-can-t-shut-up/68552067

Jim Cramer on Moderna: "Even Though the Stock's on the Mend, There Are Many Pharma and Biotech Names That I Like Better"

Jim Cramer commented on Moderna, noting its recent significant rise from 2021 lows and the potential for personalized cancer vaccines, but emphasized that it would likely remain unprofitable for years. He therefore prefers other pharma and biotech names, specifically mentioning Regeneron. Cramer highlighted Moderna's projected return to revenue growth in 2026 but advised investors to look at other companies in the sector.

https://finviz.com/news/299975/jim-cramer-on-moderna-even-though-the-stocks-on-the-mend-there-are-many-pharma-and-biotech-names-that-i-like-better

Jim Cramer on Moderna: “Even Though the Stock’s on the Mend, There Are Many Pharma and Biotech Names That I Like Better”

Jim Cramer commented on Moderna, noting its recent significant stock recovery after a steep decline but expressed a preference for other pharma and biotech names. He highlighted that Moderna is likely to remain unprofitable for years, despite expectations of revenue growth in 2026 and potential success with personalized cancer vaccines. Cramer specifically mentioned Regeneron as a better option, while the article also suggests that certain AI stocks may offer higher returns than Moderna.

https://www.insidermonkey.com/blog/jim-cramer-on-moderna-even-though-the-stocks-on-the-mend-there-are-many-pharma-and-biotech-names-that-i-like-better-1688842/

Trending Today

Shiba Inu ($SHIB) Crypto Forecast: Up 6.1% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.0% Today

Regeneron Pharmaceuticals Inc. Price History

30.04.2025 - REGN Stock was down 18.4%

• Mixed results from late-stage COPD studies conducted by Regeneron and SNY could have led to investor uncertainty and a sell-off of REGN shares.
• Meeting the primary endpoint in one trial but missing in another may have raised concerns about the drug's overall effectiveness and potential market approval.
• The uncertainty surrounding future plans for itepekimab in treating COPD could have contributed to the bearish market movement of REGN today.

18.08.2025 - REGN Stock was down 0.1%

• Despite promising results from a Phase 3 study on Garetosmab demonstrating a notable decrease in new bone lesions and favorable tolerability, the stock's decline may be linked to factors like general market sentiment or profit-taking.
• Concerns among investors may stem from the anticipation of a Wall Street trader's upcoming strategy unveiling, leading to apprehension and selling pressure on REGN shares.
• The drop in stock value may also reflect broader industry patterns or external market conditions affecting biotech stocks, resulting in a retreat in Regeneron's stock price.

01.07.2025 - REGN Stock was down 1.9%

• The stock had a bearish movement as analysts are expecting lower Q2 earnings compared to the year-ago period.
• The anticipated decrease in quarterly earnings to $8.43 per share, down from $11.56 per share, likely contributed to the bearish trend.
• Despite the long-term outperformance of Regeneron Pharmaceuticals, short-term concerns about earnings may have led to the negative market movement.
• Investors may be reacting to the revised forecasts ahead of the earnings call, causing a dip in the stock price.

13.00.2026 - REGN Stock was down 5.4%

• A notable investor, PKO Investment Management Joint Stock Co, reduced its stake in Regeneron Pharmaceuticals by 40.4%, potentially sparking concerns among investors and contributing to the stock sell-off.
• The focus on AbbVie's MFN drug pricing agreement and US R&D commitment may have diverted attention from Regeneron, impacting its stock negatively.
• Raymond James increased Regeneron's price target to $820 from $800, displaying long-term confidence in the company, although short-term profit-taking behavior could have influenced the immediate market reaction.
• Strong financial performance and favorable analyst recommendations support an optimistic outlook on Regeneron, suggesting that the recent bearish movement might be a temporary decline amidst overall positive sentiment towards the company.

28.09.2025 - REGN Stock was up 6.5%

• The upcoming Q3 earnings report for Regeneron is expected to focus on the performance of Dupixent and Eylea sales.
• Investors are optimistic about the potential of higher profits from Dupixent offsetting any decline in Eylea sales.
• The strong uptake of Eylea HD amid competition is also a key factor driving positive sentiment towards REGN stock.
• Overall, the market seems to be reacting positively to the potential growth prospects highlighted in the upcoming earnings report, leading to the bullish movement in REGN stock.

02.11.2025 - REGN Stock was down 5.7%

• The bearish movement in REGN's stock today can be attributed to Quadrant Capital Group LLC selling 688 shares, reducing its stake in the company by 25.6%. This sell-off might have created a negative sentiment among investors, leading to a decline in the stock price.
• Despite surpassing earnings expectations and maintaining strong profitability, REGN's stock underperformed on a day when the overall market, as represented by the S&P 500 Index and Dow Jones Industrial Average, also experienced losses. This broader market trend could have contributed to the downward pressure on REGN's stock.
• The partnership with Tessera Therapeutics to develop a gene-editing therapy for a rare disorder highlights REGN's commitment to innovation. However, heightened competition and potential regulatory delays mentioned in recent sources may have raised concerns among investors, impacting the stock price negatively.
• The overall positive outlook on REGN, with analysts rating it a "Moderate Buy" and the company announcing a quarterly dividend, suggests that the bearish movement today could be a short-term correction amidst a backdrop of long-term growth potential.

05.01.2026 - REGN Stock was down 0.4%

• The bearish movement in Regeneron's stock could be attributed to the overall negative sentiment surrounding the biotech sector, as highlighted by concerns over gene therapy safety issues at Sarepta Therapeutics and the competitive landscape.
• The selling of Ocular Therapeutix stock by its COO amidst a significant price drop and concerns about overvaluation in the sector may have added to the bearish pressure on biotech stocks, including Regeneron.
• Comments on Moderna and preference for other pharma and biotech names, particularly mentioning Regeneron as a more favorable option, could have influenced investor sentiment and contributed to the downward movement in Regeneron's stock price.
• The overall market perception of biotech companies may have led to profit-taking and a shift in investment focus away from companies like Regeneron, impacting its stock performance negatively.

08.04.2025 - REGN Stock was down 6.5%

• The stock price of Regeneron Pharmaceuticals experienced a significant decline today, despite a slight increase in the current market session.
• The downward trend in the stock price could be attributed to the overall market sentiment affecting biotech and pharmaceutical companies.
• Investors might be reacting to the stock's performance over the past month and year, where it has shown a notable decrease, possibly leading to profit-taking or market corrections.
• While Regeneron Pharmaceuticals has historically outperformed the market over the long term, short-term fluctuations can be influenced by various factors, including industry news and market conditions.

11.11.2025 - REGN Stock was up 5.6%

• Intact Investment Management Inc. significantly increasing its stake in REGN indicates growing confidence in the company's future prospects, potentially contributing to the bullish movement.
• Positive early data on Regeneron's Lynozyfic monotherapy for multiple myeloma patients showcases the company's promising developments in the oncology sector, boosting investor sentiment.
• Increasing the price target for REGN reflects optimism in the company's performance, aligning with the overall bullish trend in the market.
• The strong performance of AbbVie and Genmab's Epkinly at the ASH Annual Meeting may have positively influenced the biotech sector as a whole, indirectly benefiting companies like Regeneron.

10.05.2025 - REGN Stock was up 5.1%

• The bullish movement in REGN stock today can be attributed to the positive news of expanding its pipeline through a strategic deal in the obesity drug market. Investors seem optimistic about the company's efforts to address challenges in its existing portfolio and capitalize on new opportunities for growth, leading to increased confidence and buying interest in the stock.

07.00.2026 - REGN Stock was up 5.2%

• Regeneron's stock rose by 2.9% following an upgrade in its rating to 'Buy' by Bank of America Securities, which also raised the price target to $860. A similar upgrade came from Citi, setting a price target of $900. These positive evaluations by analysts boosted confidence among investors regarding the company's future outlook.
• Merit Financial Group LLC notably increased its stake in Regeneron during the third quarter, indicating strong financial performance that surpassed analyst projections. This move further contributed to the overall positive trend in the company's stock value.
• The projected growth in the Diabetic Macular Edema (DME) market, where Regeneron holds a significant position, also added to the favorable prospects for the company. Forecasts suggest that the market for DME could reach US$ 7.44 billion by 2033, driven by advancements in retinal therapies. This anticipated growth aligns well with Regeneron's standing in the industry.

01.09.2025 - REGN Stock was up 5.3%

• The momentum could be linked to the FDA's approval for the label extension of REGN's cholesterol drug Evkeeza, permitting its usage in children as young as one suffering from severe familial hypercholesterolemia.
• The FDA's endorsement for expanding the utilization of Regeneron's Evkeeza to infants with a rare cholesterol disorder may have instilled confidence in investors regarding the company's pipeline and prospective revenue.
• Anticipation surrounding Regeneron's forthcoming third-quarter financial and operating results announcement might also be fostering optimism among investors, who foresee strong performance and growth opportunities.